

June 01, 2026

To, National Stock Exchange of India Limited, “Exchange Plaza”, 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex Bandra (East), Mumbai – 400 051	To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	Scrip Code: 532296
ISIN: INE935A01035	ISIN: INE935A01035
Our Reference No. 18/26-27	Our Reference No. 18/26-27

Dear Sir/ Madam,

**Sub.: Audio recording of Q4 FY 2025-26 Earnings Call held on June 01, 2026**

Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q4 FY 2025-26 Earnings Call held on June 01, 2026 on the website of the Company at [https://glenmark.b-cdn.net/gpl\\_pdfs/Financials/Quarterly/Earnings%20Call%20Recording%20Q4%20FY26.mp3](https://glenmark.b-cdn.net/gpl_pdfs/Financials/Quarterly/Earnings%20Call%20Recording%20Q4%20FY26.mp3).

Request you to kindly take the same on record.

Thanking you.

Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**

**Rashmi Khandelwal**  
**Company Secretary & Compliance Officer**  
**ACS - 28839**

**Glenmark Pharmaceuticals Limited**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)